# Per Langoe

> Per Langoe is the CEO of GT Medical Technologies, the Tempe, Arizona company behind GammaTile, an FDA-cleared radiation therapy tile that gets sewn into the brain the same moment a tumor is removed. He arrived in February 2024 after co-founding and selling Palette Life Sciences to Teleflex for $600 million, bringing more than two decades in radiation oncology commercialization from Pharmacia, Q-Med, Galderma and Nestle Skin Health.

- **Role:** Chief Executive Officer at GT Medical Technologies, Inc.
- **Organizations:** GT Medical Technologies, Palette Life Sciences, Nestle Skin Health, Galderma, Q-Med, Pharmacia Corporation, ProstaLund AB
- **From:** Sweden
- **Nationality:** Swedish
- **Education:** MSc in Business Studies and Economics (major in Business Studies), Uppsala University, Sweden, BSc in Business Administration and Economics (major in International Business Studies), Uppsala University, Sweden
- **Known for:** Co-founded Palette Life Sciences and led it to a $600M acquisition by Teleflex in 2023, Raised $100M Series E for GT Medical Technologies in June 2026, Scaled GammaTile deployment to roughly 120 of ~200 addressable US institutions

## Career timeline

- **early career** — Roles at Pharmacia Corporation and Q-Med in Sweden
- **later** — Executive roles at Galderma and Nestle Skin Health
- **pre-2023** — Co-founder, President and CEO of Palette Life Sciences
- **2023** — Palette Life Sciences acquired by Teleflex for $600 million
- **2024-02** — Named CEO of GT Medical Technologies, succeeding founding CEO Matt Likens
- **2025-01** — GT Medical raises $37M initial close of Series D
- **2025-08** — 2,000th patient treated with GammaTile
- **2025** — $53M oversubscribed Series D final close
- **2026-06** — $100M oversubscribed Series E close

## Achievements

- Co-founded Palette Life Sciences and led it to a $600M acquisition by Teleflex in 2023
- Raised $100M Series E for GT Medical Technologies in June 2026
- Scaled GammaTile deployment to roughly 120 of ~200 addressable US institutions
- Reached 2,000th-patient milestone with GammaTile in August 2025
- Initiated the BRIDGES trial for GammaTile in newly diagnosed glioblastoma

## Latest updates

- **2026-06** — GT Medical Technologies closed a $100M oversubscribed Series E financing.
- **2025-08** — Announced 2,000th patient treated with GammaTile.
- **2025** — Announced first patients treated in the BRIDGES trial for newly diagnosed glioblastoma.

## Links

- Website: https://gtmedtech.com
- LinkedIn: https://www.linkedin.com/in/per-langoe-62a2244
- Twitter/X: https://twitter.com/gammatile
- Facebook: https://www.facebook.com/GammaTile/

---

Profile page: https://yespress.io/per-langoe
Published by YesPress — https://yespress.io
Last updated: 2026-07-09